In addition, the dual InsR/IGF-IR inhibitor linsitinib can prevent the emergence of breast cancer cells that are resistant to long-term estrogen deprivation or antiestrogen treatment and inhibit growth of established ER+ breast cancer xenografts in ovariectomized mice [107]. Here, ESR1 is linked to breast carcinoma.